<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:34:06Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7955396" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7955396</identifier>
        <datestamp>2021-03-17</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7955396</article-id>
              <article-id pub-id-type="pmcid">PMC7955396</article-id>
              <article-id pub-id-type="pmc-uid">7955396</article-id>
              <article-id pub-id-type="pmid">33305660</article-id>
              <article-id pub-id-type="pmid">33305660</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.120.016495</article-id>
              <article-id pub-id-type="publisher-id">JAH35604</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Coronary Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial</article-title>
                <alt-title alt-title-type="right-running-head">Platelet Reactivity During Ticagrelor Monotherapy</alt-title>
                <alt-title alt-title-type="left-running-head">Johnson et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah35604-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Thomas W.</given-names>
                  </name>
                  <degrees>BSc, MBBS, MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4638-601X</contrib-id>
                  <xref ref-type="aff" rid="jah35604-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>tom.johnson@uhbw.nhs.uk</email>
                  </address>
                </contrib>
                <contrib id="jah35604-cr-0002" contrib-type="author">
                  <name>
                    <surname>Baos</surname>
                    <given-names>Sarah</given-names>
                  </name>
                  <degrees>BSc (Hons), PhD</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0003" contrib-type="author">
                  <name>
                    <surname>Collett</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <degrees>BSc, MSc</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0004" contrib-type="author">
                  <name>
                    <surname>Hutchinson</surname>
                    <given-names>James L.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0005" contrib-type="author">
                  <name>
                    <surname>Nkau</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0006" contrib-type="author">
                  <name>
                    <surname>Molina</surname>
                    <given-names>Maria</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0007" contrib-type="author">
                  <name>
                    <surname>Aungraheeta</surname>
                    <given-names>Riyaad</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0008" contrib-type="author">
                  <name>
                    <surname>Reilly‐Stitt</surname>
                    <given-names>Christopher</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0009" contrib-type="author">
                  <name>
                    <surname>Bowles</surname>
                    <given-names>Ruth</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0010" contrib-type="author">
                  <name>
                    <surname>Reeves</surname>
                    <given-names>Barnaby C.</given-names>
                  </name>
                  <degrees>BA (Hons), MSc, D.Phil</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0011" contrib-type="author">
                  <name>
                    <surname>Rogers</surname>
                    <given-names>Chris A.</given-names>
                  </name>
                  <degrees>BSc (Hons), PGCE, PhD</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0012" contrib-type="author">
                  <name>
                    <surname>Mundell</surname>
                    <given-names>Stuart J</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0013" contrib-type="author">
                  <name>
                    <surname>Baumbach</surname>
                    <given-names>Andreas</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0004">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="jah35604-note-0002">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib id="jah35604-cr-0014" contrib-type="author">
                  <name>
                    <surname>Mumford</surname>
                    <given-names>Andrew D.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35604-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35604-aff-0005">
                    <sup>5</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="jah35604-note-0002">
                    <sup>*</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah35604-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>Bristol Heart Institute</institution>
                <institution>University Hospitals Bristol &amp; Weston NHS Foundation Trust</institution>
                <city>Bristol</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jah35604-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Clinical Trials and Evaluation Unit</named-content>
                <institution>Bristol Trials Centre</institution>
                <institution>Bristol Medical School</institution>
                <institution>University of Bristol</institution>
                <city>Bristol</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jah35604-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">School of Physiology, Pharmacology and Neuroscience</named-content>
                <institution>University of Bristol</institution>
                <city>Bristol</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jah35604-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>William Harvey Research Institute</institution>
                <institution>Queen Mary University of London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jah35604-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">School of Cellular and Molecular Medicine</named-content>
                <institution>University of Bristol</institution>
                <city>Bristol</city>
                <country country="GB">UK</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Thomas Johnson, BSc, MBBS, MD, FESC, Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Marlborough Street, Bristol BS2 8HW, UK. E‐mail: <email>tom.johnson@uhbw.nhs.uk</email><break/></corresp>
                <fn id="jah35604-note-0002">
                  <label>*</label>
                  <p>Prof. Baumbach and Dr. Mumford contributed equally to this work.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>11</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>15</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <volume>9</volume>
              <issue>24</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v9.24</issue-id>
              <elocation-id>e016495</elocation-id>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>5</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>06</day>
                  <month>9</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell<copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-9-e016495.pdf"/>
              <abstract id="jah35604-abs-0001">
                <sec id="jah35604-sec-0001">
                  <title>Background</title>
                  <p>To assess differences in platelet inhibition during ticagrelor monotherapy (TIC) or dual therapy with ticagrelor and aspirin (TIC+ASP) in patients after percutaneous coronary intervention using a comprehensive panel of functional tests.</p>
                </sec>
                <sec id="jah35604-sec-0002">
                  <title>Methods and Results</title>
                  <p>In a single‐center parallel group, open label, randomized controlled trial, 110 participants were randomized to receive either TIC (n=55) or TIC+ASP (n=55) for 4 weeks. The primary outcome was the platelet aggregation response with 10 μmol/L thrombin receptor activation peptide‐6 (TRAP‐6). The secondary outcomes were platelet aggregation responses and binding of surface activation markers with a panel of other activators. The mean percentage aggregation for 10 μmol/L TRAP‐6 was similar for the TIC and TIC+ASP groups (mean difference+4.29; 95% CI, −0.87 to +9.46). Aggregation was higher in the TIC group compared with the TIC+ASP group with 1 μg/mL (+6.47; +2.04 to +10.90) and 0.5 μg/mL (+14.00; +7.63 to +20.39) collagen related peptide. Aggregation responses with 5 μmol/L TRAP‐6, 5 μmol/L or 2.5 μmol/L thromboxane A<sub>2</sub> receptor agonist and surface activation marker binding with 5 μmol/L TRAP‐6 or 0.5 μg/mL collagen related peptide were the same between the treatment groups.</p>
                </sec>
                <sec id="jah35604-sec-0003">
                  <title>Conclusions</title>
                  <p>Patients with PCI show similar levels of inhibition of most platelet activation pathways with TIC compared with dual therapy with TIC + ASP. However, the greater aggregation response with collagen related peptide during TIC indicates incomplete inhibition of glycoprotein VI (collagen) receptor‐mediated platelet activation. This difference in pharmacodynamic response to anti‐platelet medication may contribute to the lower bleeding rates observed with TIC compared with dual antiplatelet therapy in recent clinical trials.</p>
                </sec>
                <sec id="jah35604-sec-0004">
                  <title>Registration Information</title>
                  <p>URL: <ext-link ext-link-type="uri" xlink:href="https://www.isrctn.com">https://www.isrctn.com</ext-link>; Unique Identifier ISRCTN84335288.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah35604-kwd-0001">aspirin</kwd>
                <kwd id="jah35604-kwd-0002">dual anti‐platelet therapy</kwd>
                <kwd id="jah35604-kwd-0003">platelet activation</kwd>
                <kwd id="jah35604-kwd-0004">ticagrelor monotherapy</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Pharmacology</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Astra Zeneca Investigator</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>NIHR Biomedical Research Centre</funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>University Hospitals Bristol NHS Foundation Trust </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/100012141</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>University of Bristol </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100000883</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>CTEU</funding-source>
                </award-group>
                <award-group id="funding-0006">
                  <funding-source>Bristol Trials Centre</funding-source>
                </award-group>
                <award-group id="funding-0007">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institute for Health Research (NIHR) </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100000272</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0008">
                  <funding-source>NHS</funding-source>
                </award-group>
                <award-group id="funding-0009">
                  <funding-source>Department of Health and Social Care</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="1"/>
                <page-count count="10"/>
                <word-count count="6337"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>15 December 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.7 mode:remove_FC converted:19.02.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah35604-cit-1001">(<source xml:lang="en">J. Am. Heart Assoc.</source>
<year>2020</year>;<volume>9</volume>:<elocation-id>e05604</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.120.016495</pub-id>.)</mixed-citation>
              </p>
              <fn-group id="jah35604-ntgp-0001">
                <fn id="jah35604-note-0001">
                  <p>Supplementary Material for this article is available at <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.016495">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.016495</ext-link>.</p>
                </fn>
                <fn id="jah35604-note-0003">
                  <p>For Sources of Funding and Disclosures, see page 8.</p>
                </fn>
                <fn id="jah35604-note-0004">
                  <p>See Editorial by Capodanno and Angiolillo</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah35604-body-0001">
            <def-list list-content="abbreviations" id="jah35604-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>AA</term>
                <def>
                  <p>arachidonic acid</p>
                </def>
              </def-item>
              <def-item>
                <term>CD62P</term>
                <def>
                  <p>platelet surface P‐selectin</p>
                </def>
              </def-item>
              <def-item>
                <term>CRP</term>
                <def>
                  <p>collagen related peptide</p>
                </def>
              </def-item>
              <def-item>
                <term>DAPT</term>
                <def>
                  <p>dual antiplatelet therapy</p>
                </def>
              </def-item>
              <def-item>
                <term>GPVI receptor</term>
                <def>
                  <p>platelet glycoprotein VI receptor</p>
                </def>
              </def-item>
              <def-item>
                <term>PAC‐1</term>
                <def>
                  <p>activated GP IIb/IIIa</p>
                </def>
              </def-item>
              <def-item>
                <term>TIC</term>
                <def>
                  <p>ticagrelor monotherapy</p>
                </def>
              </def-item>
              <def-item>
                <term>TIC+ASP</term>
                <def>
                  <p>ticagrelor and aspirin dual therapy</p>
                </def>
              </def-item>
              <def-item>
                <term>TRAP‐6</term>
                <def>
                  <p>thrombin receptor activation peptide‐6</p>
                </def>
              </def-item>
              <def-item>
                <term>TxA2</term>
                <def>
                  <p>thromboxane A2</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah35604-blkfxd-0001" orientation="portrait">
                <sec id="jah35604-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah35604-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah35604-list-0001">
                        <list-item>
                          <p>In acute coronary syndrome treatment a delicate balance between ischaemic protection and bleeding exists, hence studies comparing dual anti‐platelet treatment with potent ADP receptor antagonist monotherapy ‐ TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) is the first dedicated study to assess the pharmacodynamic effects of ticagrelor monotherapy against aspirin and ticagrelor combination therapy in patients who have previously undergone percutaneous coronary intervention.</p>
                        </list-item>
                        <list-item>
                          <p>Ticagrelor monotherapy provides similar platelet aggregation responses to agonists of the thrombin and thromboxane A<sub>2</sub> receptor compared with dual therapy but the aggregation response to an agonist specific to the platelet glycoprotein VI receptor (essential for normal haemostasis) was higher in the ticagrelor monotherapy group.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah35604-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah35604-list-0002">
                        <list-item>
                          <p>Considered alongside clinical outcome data, our findings support comprehensive platelet inhibition with dual anti‐platelet therapy, early after percutaneous coronary intervention, when thrombotic risk is highest but suggest a potential advantage for subsequent cessation of aspirin to diminish bleeding by reducing platelet inhibition and specifically minimization of gastrointestinal tract bleeding for which aspirin is a contributory factor.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah35604-sec-0009">
              <p>Dual anti‐platelet therapy (DAPT) with aspirin and a P2Y<sub>12</sub> antagonist to additionally supress the ADP platelet activation pathway reduces the composite risk of myocardial infarction and cardiovascular death after percutaneous coronary intervention (PCI) when compared with aspirin monotherapy.<xref rid="jah35604-bib-0001" ref-type="ref"><sup>1</sup></xref>, <xref rid="jah35604-bib-0002" ref-type="ref"><sup>2</sup></xref> Consequently, DAPT is the current standard anti‐thrombotic regime.<xref rid="jah35604-bib-0003" ref-type="ref"><sup>3</sup></xref>, <xref rid="jah35604-bib-0004" ref-type="ref"><sup>4</sup></xref> Potent P2Y<sub>12</sub> antagonists improve ischaemic protection when compared with clopidogrel, because they enable more consistent suppression of ADP‐mediated platelet activation.<xref rid="jah35604-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35604-bib-0006" ref-type="ref"><sup>6</sup></xref>, <xref rid="jah35604-bib-0007" ref-type="ref"><sup>7</sup></xref> However, the greater anti‐thrombotic effect of potent P2Y<sub>12</sub> antagonists is accompanied by increased bleeding.<xref rid="jah35604-bib-0008" ref-type="ref"><sup>8</sup></xref>
</p>
              <p>It has long been recognized that the ADP platelet activation pathway utilizes signalling mediators and effectors that are partially shared with the thromboxane A<sub>2</sub> (TxA<sub>2</sub>) activation pathway, the target of inhibition by aspirin.<xref rid="jah35604-bib-0009" ref-type="ref"><sup>9</sup></xref>, <xref rid="jah35604-bib-0010" ref-type="ref"><sup>10</sup></xref>, <xref rid="jah35604-bib-0011" ref-type="ref"><sup>11</sup></xref> In view of this potential redundancy, monotherapy with a potent P2Y<sub>12</sub> antagonist has been proposed as an alternative to DAPT, maintaining anti‐thrombotic effect whilst avoiding bleeding associated with aspirin.<xref rid="jah35604-bib-0012" ref-type="ref"><sup>12</sup></xref>, <xref rid="jah35604-bib-0013" ref-type="ref"><sup>13</sup></xref> In healthy volunteers, potent P2Y<sub>12</sub> antagonists diminish both ADP and TxA<sub>2</sub>‐mediated platelet aggregation, suggesting that additional aspirin is unnecessary for full platelet inhibition.<xref rid="jah35604-bib-0010" ref-type="ref"><sup>10</sup></xref>, <xref rid="jah35604-bib-0014" ref-type="ref"><sup>14</sup></xref> However, in other studies a P2Y<sub>12</sub> antagonist had minimal impact on the production of the TxA<sub>2</sub> metabolite, thromboxane B<sub>2</sub>, suggesting that the TxA<sub>2</sub> pathway is incompletely inhibited.<xref rid="jah35604-bib-0015" ref-type="ref"><sup>15</sup></xref>
</p>
              <p>Despite the lack of conclusive data from healthy control studies, potent P2Y<sub>12</sub> antagonist monotherapy has been compared to DAPT in several large randomized controlled trials in patients who had undergone PCI.<xref rid="jah35604-bib-0016" ref-type="ref"><sup>16</sup></xref>, <xref rid="jah35604-bib-0017" ref-type="ref"><sup>17</sup></xref>, <xref rid="jah35604-bib-0018" ref-type="ref"><sup>18</sup></xref> Patients who were switched from DAPT to P2Y<sub>12</sub> antagonist monotherapy, between 1 and 3 months after PCI, had non‐inferior composite rates of all‐cause death or ischaemic events compared with patients remaining on DAPT, suggesting equivalent antithrombotic effect.<xref rid="jah35604-bib-0017" ref-type="ref"><sup>17</sup></xref>, <xref rid="jah35604-bib-0018" ref-type="ref"><sup>18</sup></xref>, <xref rid="jah35604-bib-0019" ref-type="ref"><sup>19</sup></xref> Importantly, bleeding in patients switched to P2Y<sub>12</sub> antagonist monotherapy was either lower<xref rid="jah35604-bib-0017" ref-type="ref"><sup>17</sup></xref>, <xref rid="jah35604-bib-0019" ref-type="ref"><sup>19</sup></xref> or non‐inferior<xref rid="jah35604-bib-0018" ref-type="ref"><sup>18</sup></xref> when compared with patients remaining on DAPT.</p>
              <p>Translation of the results from these trials into clinical practice remains unclear, primarily because the specific nature of the study designs and subject selection limits generalization of the results to all patients.<xref rid="jah35604-bib-0020" ref-type="ref"><sup>20</sup></xref> In particular, the possible implementation of P2Y<sub>12</sub> antagonist monotherapy to specific patient subgroups is currently hampered by the lack of a mechanistic understanding of the differences between the P2Y<sub>12</sub> antagonist monotherapy and DAPT groups observed in the trials.<xref rid="jah35604-bib-0016" ref-type="ref"><sup>16</sup></xref> In order to quantify differences in the pharmacodynamic effect of P2Y<sub>12</sub> antagonist monotherapy compared to DAPT, we randomized patients with PCI to receive either TIC or DAPT with ticagrelor and aspirin (TIC + ASP) and performed a comprehensive panel of platelet functional tests on blood samples.</p>
            </sec>
            <sec sec-type="methods" id="jah35604-sec-0010">
              <title>Methods</title>
              <sec id="jah35604-sec-0011">
                <title>TEMPLATE Trial Design and Interventions</title>
                <p>The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) study was a single‐center, open‐label, parallel group RCT (ISRCTN84335288). The study was approved by a UK Research Ethics Committee (14/SC/1309) and was authorized by the Medicines and Healthcare Regulatory Agency (EUDRACT N<sup>o</sup> 2013‐002734‐20). The study protocol has been reported previously.<xref rid="jah35604-bib-0021" ref-type="ref"><sup>21</sup></xref> The data generated from the trial are available from the corresponding author on request. The request must include a specification of the data requested and justification for that request (i.e. a statement of purpose for which the data are required). The data may not be released unless all Bristol Trials Centre and Sponsor requirements are fulfilled (e.g. protocol, sample size calculation, valid National Research Ethics Service Committee and Health Research Authority approval if appropriate, a collaborative arrangement in place between the Sponsor and the external body).</p>
                <p>Patients under the care of the Bristol Heart Institute, Bristol, UK were eligible for inclusion if they were adults aged &gt;18 years receiving DAPT with aspirin and any P2Y<sub>12</sub> antagonist after PCI for acute coronary syndrome (ACS) and for which there was a clinical intention to transfer to aspirin monotherapy. Patients were ineligible if there was a contra‐indication to ticagrelor, if prior treatment with DAPT had been interrupted because of bleeding, if they were pregnant or breast feeding or if the patient was (or was a partner of) a woman with child‐bearing potential unwilling to use contraception. Twelve months after the index PCI, when DAPT would normally be switched to aspirin monotherapy, consenting patients were randomized using a internet‐based computer system ensuring allocation concealment. No blinding was used. Patients were allocated in a 1:1 ratio to receive either TIC (TIC group; ticagrelor 180 mg then 90 mg twice per day), or DAPT with ticagrelor and aspirin (TIC+ASP group; ticagrelor 180 mg then 90 mg twice per day plus aspirin 75 mg once per day), for a total of 4 weeks. The ticagrelor doses in the treatment arms were selected to reproduce current standard DAPT given for the first 12 months after PCI. Participants in both groups were then switched to monotherapy with aspirin 75 mg once per day for 4 weeks and returned to standard care. Blood samples were obtained during initial DAPT (blood sample 1), 4 weeks after allocation to the TIC or TIC+ASP groups (blood sample 2) and 4 weeks after transfer to aspirin monotherapy (blood sample 3; Figure <xref rid="jah35604-fig-0001" ref-type="fig">1</xref>). Safety outcomes were collected for the duration of the study or until participant withdrawal.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35604-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <title>Trial design.</title>
                    <p>DAPT indicates dual antiplatelet therapy; and PCI, percutaneous coronary intervention</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-9-e016495-g001"/>
                </fig>
              </sec>
              <sec id="jah35604-sec-0012">
                <title>Analysis of Blood Samples</title>
                <p>Functional responses of platelet rich plasma obtained from venous blood samples were analyzed by light transmission aggregation using a PAP‐8E platelet aggregometer (BioData, Horsham, PA, USA).<xref rid="jah35604-bib-0021" ref-type="ref"><sup>21</sup></xref> The platelets were stimulated with 10 μmol/L and 5 μmol/L thrombin receptor activation peptide‐6 (TRAP‐6), 1 μg/mL and 0.5 μg/mL collagen related peptide (CRP), 2.5 μmol/L and 5 μmol/L thromboxane A<sub>2</sub> (TxA<sub>2</sub>) receptor agonist (U46619), 1 mmol/L arachidonic acid (AA) or 10 μmol/L ADP. Reagents were obtained from Hart biologicals (Hartlepool, UK) except for CRP (University of Cambridge, UK). Results were recorded as the maximum amplitude of aggregation, expressed as a percentage of the difference in light transmission between platelet rich plasma and a plasma control.</p>
                <p>Platelet surface activation markers were measured in unstimulated platelet rich plasma and in platelet rich plasma after stimulation with 1 μg/mL CRP or 5 μmol/L TRAP‐6 by incubated the samples with PE‐conjugated anti‐CD62P (Becton Dickinson, Oxford, UK) and FITC‐conjugated PAC‐1 antibodies (Becton Dickinson) for 10 minutes at room temperature and then fixing in 1% paraformaldehyde. Antibody binding was measured on a BD FACSCanto TM II (BD Biosciences) and reported as the median fluorescence intensity (MFI) of antibody binding in unstimulated platelets and the increase in MFI (ΔMFI) of antibody binding after stimulation.</p>
              </sec>
              <sec id="jah35604-sec-0013">
                <title>Outcomes</title>
                <p>The primary outcome was the maximum amplitude of platelet aggregation after stimulation with 10 μmol/L TRAP‐6. Secondary outcomes were the maximum amplitude of aggregation with the remaining activators and the binding of platelet surface activation markers. Outcomes were compared in blood sample 2, taken at the end of the intervention period.</p>
              </sec>
              <sec id="jah35604-sec-0014">
                <title>Statistical Analysis</title>
                <p>The sample size of 110 participants was chosen to provide a 95% CI of ±0.35 SD for the mean difference in 10 μmol/L TRAP‐6 between groups, assuming correlation between pre‐ and post‐treatment platelet function results of 0.5, with no crossover, and allowing for 10% drop‐out.</p>
                <p>Participants were analyzed on an intention‐to‐treat basis and analyses were carried out according to a prespecified statistical analysis plan. To minimize the type 1 error rate, it was agreed a priori that the difference in the aggregation response with 10 μmol/L TRAP‐6 (primary outcome) and in the aggregation responses with 1 μg/mL CRP, 1 mmol/L AA and 10 μmol/L ADP would be quantified. Differences in aggregation responses for the remaining agonists were quantified posthoc. The binding of platelet surface activation markers was described, but differences were not quantified.</p>
                <p>Differences between the treatment groups were assessed using longitudinal mixed effects multiple linear regression models that included data from all blood samples, with patients fitted as random intercepts and sample number as random slopes (depending on model fit, with unstructured covariance matrices). Treatment group, sample number and their interaction were included as fixed effects. Models were compared using the likelihood ratio test. Differences between the treatment groups were expressed as the difference in mean percentage of the maximum amplitude of aggregation in blood sample 2, representing the model‐adjusted absolute difference between the responses in the TIC+ASP group as the reference. All <italic>P</italic> values are 2‐sided. Analyses were conducted using Stata Statistical Software Release 15 (StataCorp, College Station, TX).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah35604-sec-0015">
              <title>Results</title>
              <sec id="jah35604-sec-0016">
                <title>Recruitment and Follow‐up</title>
                <p>Between December 2015 and July 2017, all 2967 patients listed for PCI at the study center underwent pre‐screening to identify patients who could immediately be excluded because they did not meet the eligibility criteria. The remaining 1186 patients underwent full screening for eligibility and were invited to join the study. Within this group, 182 patients were confirmed as eligible and expressed interest in participation. A total of 115 patients were approached, 112 gave consent and 110 were randomized (55 to TIC and 55 to TIC+ASP; Figure <xref rid="jah35604-fig-0002" ref-type="fig">2</xref>). All participants provided the first blood sample at recruitment. Seven participants withdrew during the intervention period (first period of 4 weeks) and 1 withdrew after the trial intervention period (second period of 4 weeks). The reasons for withdrawal were participant request for an unspecified reason (3); participant unable to comply with study visits (2); primary care physician request to withdraw (1) and death of participant (1). One further participant was withdrawn because he was found to be ineligible from medical records that became available only after randomization.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35604-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <title>Screening, eligibility, randomization and blood sampling.</title>
                    <p>ASP indicates aspirin; and TIC, ticagrelor monotherapy.</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JAH3-9-e016495-g002"/>
                </fig>
              </sec>
              <sec id="jah35604-sec-0017">
                <title>Participant Characteristics</title>
                <p>The clinical characteristics of the participants in the 2 groups were similar (Table <xref rid="jah35604-tbl-0001" ref-type="table">1</xref>). Overall, 88 participants were male and mean age was 67 years. The median time from PCI to randomization was 366 days (IQR 360, 374). All participants had received DAPT continuously since PCI, comprising aspirin and either ticagrelor (44%), clopidogrel (35%) or prasugrel (21%) according to standard institutional treatment protocols.</p>
                <table-wrap id="jah35604-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Characteristics of the Trial Population</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1"/>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">TIC+ASP (n=55)</th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">TIC alone (n=55)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">n</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">%</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">n</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">%</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Clinical characteristics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Age, y</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">67.3 (10.3)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">66.1 (11.8)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Sex</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Female</td>
                        <td align="left" rowspan="1" colspan="1">11/55</td>
                        <td align="left" rowspan="1" colspan="1">20</td>
                        <td align="left" rowspan="1" colspan="1">11/55</td>
                        <td align="left" rowspan="1" colspan="1">20</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Male</td>
                        <td align="left" rowspan="1" colspan="1">44/55</td>
                        <td align="left" rowspan="1" colspan="1">80</td>
                        <td align="left" rowspan="1" colspan="1">44/55</td>
                        <td align="left" rowspan="1" colspan="1">80</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">27.6 (3.8)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">27.0 (4.9)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Smoking</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Active smoker</td>
                        <td align="left" rowspan="1" colspan="1">6/55</td>
                        <td align="left" rowspan="1" colspan="1">11</td>
                        <td align="left" rowspan="1" colspan="1">7/55</td>
                        <td align="left" rowspan="1" colspan="1">13</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ex‐smoker of more than 1 mo</td>
                        <td align="left" rowspan="1" colspan="1">29/55</td>
                        <td align="left" rowspan="1" colspan="1">53</td>
                        <td align="left" rowspan="1" colspan="1">27/55</td>
                        <td align="left" rowspan="1" colspan="1">49</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Never smoked</td>
                        <td align="left" rowspan="1" colspan="1">20/55</td>
                        <td align="left" rowspan="1" colspan="1">36</td>
                        <td align="left" rowspan="1" colspan="1">21/55</td>
                        <td align="left" rowspan="1" colspan="1">38</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Family history of heart disease</td>
                        <td align="left" rowspan="1" colspan="1">29/55</td>
                        <td align="left" rowspan="1" colspan="1">53</td>
                        <td align="left" rowspan="1" colspan="1">21/55</td>
                        <td align="left" rowspan="1" colspan="1">38</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension requiring treatment</td>
                        <td align="left" rowspan="1" colspan="1">26/55</td>
                        <td align="left" rowspan="1" colspan="1">47</td>
                        <td align="left" rowspan="1" colspan="1">31/55</td>
                        <td align="left" rowspan="1" colspan="1">56</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypercholesterolaemia</td>
                        <td align="left" rowspan="1" colspan="1">30/55</td>
                        <td align="left" rowspan="1" colspan="1">55</td>
                        <td align="left" rowspan="1" colspan="1">31/55</td>
                        <td align="left" rowspan="1" colspan="1">56</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Diabetes mellitus</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Insulin</td>
                        <td align="left" rowspan="1" colspan="1">3/55</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">4/55</td>
                        <td align="left" rowspan="1" colspan="1">7</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Oral hypoglycaemic or diet</td>
                        <td align="left" rowspan="1" colspan="1">6/55</td>
                        <td align="left" rowspan="1" colspan="1">11</td>
                        <td align="left" rowspan="1" colspan="1">4/55</td>
                        <td align="left" rowspan="1" colspan="1">7</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">None</td>
                        <td align="left" rowspan="1" colspan="1">46/55</td>
                        <td align="left" rowspan="1" colspan="1">84</td>
                        <td align="left" rowspan="1" colspan="1">47/55</td>
                        <td align="left" rowspan="1" colspan="1">85</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Congestive heart failure</td>
                        <td align="left" rowspan="1" colspan="1">4/55</td>
                        <td align="left" rowspan="1" colspan="1">7</td>
                        <td align="left" rowspan="1" colspan="1">1/55</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cerebrovascular disease</td>
                        <td align="left" rowspan="1" colspan="1">3/55</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">3/55</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic pulmonary disease</td>
                        <td align="left" rowspan="1" colspan="1">6/55</td>
                        <td align="left" rowspan="1" colspan="1">11</td>
                        <td align="left" rowspan="1" colspan="1">7/55</td>
                        <td align="left" rowspan="1" colspan="1">13</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral vascular disease</td>
                        <td align="left" rowspan="1" colspan="1">2/55</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">1/55</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous PCI<xref ref-type="fn" rid="jah35604-note-0005">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">12/55</td>
                        <td align="left" rowspan="1" colspan="1">22</td>
                        <td align="left" rowspan="1" colspan="1">15/55</td>
                        <td align="left" rowspan="1" colspan="1">27</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous cardiac surgery</td>
                        <td align="left" rowspan="1" colspan="1">5/55</td>
                        <td align="left" rowspan="1" colspan="1">9</td>
                        <td align="left" rowspan="1" colspan="1">4/55</td>
                        <td align="left" rowspan="1" colspan="1">7</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous myocardial infarction<xref ref-type="fn" rid="jah35604-note-0005">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">27/55</td>
                        <td align="left" rowspan="1" colspan="1">49</td>
                        <td align="left" rowspan="1" colspan="1">30/55</td>
                        <td align="left" rowspan="1" colspan="1">55</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Left ventricular function</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Good (&gt;50%)</td>
                        <td align="left" rowspan="1" colspan="1">36/53</td>
                        <td align="left" rowspan="1" colspan="1">68</td>
                        <td align="left" rowspan="1" colspan="1">38/53</td>
                        <td align="left" rowspan="1" colspan="1">72</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Moderate (30%‐50%)</td>
                        <td align="left" rowspan="1" colspan="1">17/53</td>
                        <td align="left" rowspan="1" colspan="1">32</td>
                        <td align="left" rowspan="1" colspan="1">14/53</td>
                        <td align="left" rowspan="1" colspan="1">26</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Poor (&lt;30%)</td>
                        <td align="left" rowspan="1" colspan="1">0/53</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1/53</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Coronary artery disease</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Single vessel</td>
                        <td align="left" rowspan="1" colspan="1">26/55</td>
                        <td align="left" rowspan="1" colspan="1">47</td>
                        <td align="left" rowspan="1" colspan="1">28/55</td>
                        <td align="left" rowspan="1" colspan="1">51</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Double vessel</td>
                        <td align="left" rowspan="1" colspan="1">21/55</td>
                        <td align="left" rowspan="1" colspan="1">38</td>
                        <td align="left" rowspan="1" colspan="1">14/55</td>
                        <td align="left" rowspan="1" colspan="1">25</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Triple vessel</td>
                        <td align="left" rowspan="1" colspan="1">8/55</td>
                        <td align="left" rowspan="1" colspan="1">15</td>
                        <td align="left" rowspan="1" colspan="1">13/55</td>
                        <td align="left" rowspan="1" colspan="1">24</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Anti‐platelet medication before randomization</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td>
                        <td align="left" rowspan="1" colspan="1">55/55</td>
                        <td align="left" rowspan="1" colspan="1">100</td>
                        <td align="left" rowspan="1" colspan="1">55/55</td>
                        <td align="left" rowspan="1" colspan="1">100</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Clopidogrel</td>
                        <td align="left" rowspan="1" colspan="1">19/55</td>
                        <td align="left" rowspan="1" colspan="1">35</td>
                        <td align="left" rowspan="1" colspan="1">20/55</td>
                        <td align="left" rowspan="1" colspan="1">36</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prasugrel</td>
                        <td align="left" rowspan="1" colspan="1">13/55</td>
                        <td align="left" rowspan="1" colspan="1">24</td>
                        <td align="left" rowspan="1" colspan="1">10/55</td>
                        <td align="left" rowspan="1" colspan="1">18</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ticagrelor</td>
                        <td align="left" rowspan="1" colspan="1">23/55</td>
                        <td align="left" rowspan="1" colspan="1">42</td>
                        <td align="left" rowspan="1" colspan="1">25/55</td>
                        <td align="left" rowspan="1" colspan="1">45</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah35604-ntgp-0002">
                    <fn id="jah35604-note-0005">
                      <label>*</label>
                      <p>Refers to percutaneous coronary intervention (PCI) of myocardial infarction prior to the index PCI considered in this study.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah35604-sec-0018">
                <title>Platelet Function 4 Weeks After Allocation to Treatment Group (Sample 2)</title>
                <p>The difference in mean percentage platelet aggregation with 10 μmol/L TRAP‐6 (primary outcome) was similar in the 2 groups (aggregation with TIC minus TIC+ASP=+4.29; 95% CI, −0.87 to +9.46; <italic>P</italic>=0.103; Figures <xref rid="jah35604-fig-0003" ref-type="fig">3A</xref> and <xref rid="jah35604-fig-0004" ref-type="fig">4</xref> and Table <xref rid="jah35604-sup-0001" ref-type="supplementary-material">S1</xref>). Considering the secondary outcomes, aggregation was higher in the TIC group compared with the TIC+ASP group with 1 μg/mL CRP (difference+6.47 (+2.04 to +10.90); <italic>P</italic>=0.004) and with 0.5 μg/mL CRP (difference +14.00 (+7.63 to +20.39); <italic>P</italic> &lt; 0.001), indicating less platelet inhibition in the TIC group. There was no difference between the groups in platelet aggregation with 5 μmol/L TRAP‐6, 2.5 μmol/L U46619 or with 5 μmol/L U46619.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35604-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <title>Platelet light transmission aggregation responses.</title>
                    <p>Data represent the maximum amplitude of aggregation responses (medians and interquartile ranges) at visit 1 (all patients receiving DAPT), visit 2 (4 weeks after allocation to either TIC or TIC+ASP groups) and visit 3 (all patients receiving aspirin alone). <italic>P</italic> values are 2‐tailed. <bold>A</bold>, Responses to thrombin receptor activation peptide 6 (TRAP‐6), collagen related peptide (CRP) and thromboxane A<sub>2</sub> receptor agonist (U46619). <bold>B</bold>, Responses to adenosine diphosphate (ADP) and arachidonic acid (AA).</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JAH3-9-e016495-g003"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah35604-fig-0004" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <title>Mean treatment differences in platelet aggregation responses in blood sample 2.</title>
                    <p>The whiskers indicate the 95% CIs of the mean treatment difference estimates. Estimates less than zero indicate that the aggregation responses in TIC+ASP group were greater than in TIC group. *represents posthoc comparisons of measures. <italic>P</italic> values are 2‐tailed. AA indicates arachidonic acid; ADP, adenosine diphosphate; CRP, collagen related peptide; TRAP‐6, thrombin receptor activation peptide 6; and U46619, thromboxane A<sub>2</sub> receptor agonist.</p>
                  </caption>
                  <graphic id="nlm-graphic-7" xlink:href="JAH3-9-e016495-g004"/>
                </fig>
                <p>As expected, platelet aggregation was markedly higher in the TIC group compared with the TIC+ASP group with 1 mmol/L AA (difference +11.68 (+8.55 to +15.95); <italic>P</italic> &lt; 0.001). (Figures <xref rid="jah35604-fig-0003" ref-type="fig">3B</xref> and <xref rid="jah35604-fig-0004" ref-type="fig">4</xref>) which is a sensitive marker of platelet inhibition with aspirin. Aggregation was similar between the treatment groups with 10 μmol/L ADP (difference +1.15 (−4.89 to +7.19); <italic>P</italic>=0.709; Figures <xref rid="jah35604-fig-0003" ref-type="fig">3B</xref> and <xref rid="jah35604-fig-0004" ref-type="fig">4</xref>) and confirmed full suppression of ADP‐mediated platelet in both groups.</p>
                <p>Participants in both groups had similarly low levels of binding of the activation markers PAC 1 and anti‐CD62P in unstimulated platelets. Although after stimulation with 5 μmol/L TRAP‐6 or 1 μg/mL CRP, binding of both PAC 1 and anti‐CD62P increased markedly, the extent of activation marker binding was similar in the 2 groups (Figure <xref rid="jah35604-fig-0005" ref-type="fig">5</xref> and Table <xref rid="jah35604-sup-0001" ref-type="supplementary-material">S2</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35604-fig-0005" orientation="portrait" position="float">
                  <label>Figure 5</label>
                  <caption>
                    <title>Platelet binding of the PAC 1 and anti‐CD62P activation markers from blood sample 2.</title>
                    <p><bold>A</bold>, baseline activation marker binding without agonist stimulation. <bold>B</bold>, the increase in activation marker binding after stimulation with thrombin receptor activation peptide 6 (TRAP‐6) 5 μmol/L or with collagen related peptide (CRP) 1μg/mL. The data are expressed as the median (interquartile range) of the median fluorescent intensity of binding of PAC 1 or anti‐CD62P.</p>
                  </caption>
                  <graphic id="nlm-graphic-9" xlink:href="JAH3-9-e016495-g005"/>
                </fig>
              </sec>
              <sec id="jah35604-sec-0019">
                <title>Platelet Function at Baseline and After Transfer to Aspirin Alone (Samples 1 and 3)</title>
                <p>No differences in aggregation or surface activation marker binding were found in blood samples 1 and 3 (Figure <xref rid="jah35604-fig-0003" ref-type="fig">3</xref>, Figures <xref rid="jah35604-sup-0001" ref-type="supplementary-material">S1 and S2</xref>, Tables <xref rid="jah35604-sup-0001" ref-type="supplementary-material">S1–S2</xref>), consistent with patients in both groups receiving the same classes of anti‐platelet drugs at the time of these blood samples.</p>
              </sec>
              <sec id="jah35604-sec-0020">
                <title>Adverse Outcomes</title>
                <p>A total of 258 adverse events occurred during the entire trial period (Table <xref rid="jah35604-sup-0001" ref-type="supplementary-material">S3</xref>), of which 188 occurred during the 4‐week trial intervention period (98 events in 39 patients in the TIC group and 90 events in 37 patients in the TIC+ASP group; Table <xref rid="jah35604-sup-0001" ref-type="supplementary-material">S4</xref>). There were 53 bleeding events during the 4‐week intervention period: 20 in the TIC group and 33 in the TIC+ASP group. Bleeding was predominantly subcutaneous or dermal in both groups and was mild (all bleeding events were Bleeding Academic Research Consortium Type 1).<xref rid="jah35604-bib-0022" ref-type="ref"><sup>22</sup></xref> One major adverse cardiac (fatal acute coronary syndrome) event occurred during the 4‐week trial intervention period in the TIC+ASP group.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah35604-sec-0021">
              <title>Discussion</title>
              <p>The TEMPLATE study is the first randomized controlled trial performed to assess differences between the pharmacodynamic effects of TIC and DAPT with TIC + ASP in patients who have previously undergone PCI. The study was performed in order to provide mechanistic insight into the extent of platelet inhibition with TIC. The panel of tests included functional evaluation of the major platelet receptors for thrombin and collagen which are essential for normal haemostasis and initiate pathological thrombus formation in acute coronary syndrome.<xref rid="jah35604-bib-0023" ref-type="ref"><sup>23</sup></xref>, <xref rid="jah35604-bib-0024" ref-type="ref"><sup>24</sup></xref>, <xref rid="jah35604-bib-0025" ref-type="ref"><sup>25</sup></xref> We found the pharmacodynamic effect of TIC to be similar to previous studies with groups of patients with acute coronary syndrome.<xref rid="jah35604-bib-0026" ref-type="ref"><sup>26</sup></xref>, <xref rid="jah35604-bib-0027" ref-type="ref"><sup>27</sup></xref> However our study also showed the primary outcome of platelet aggregation with 10 μmol/L TRAP‐6 was the same in patients receiving TIC compared with patients receiving DAPT. However, platelet aggregation with 1 μg/mL or 0.5 μg/mL CRP was higher in patients receiving TIC, indicating less complete platelet inhibition.</p>
              <p>After 4 weeks of the allocated treatment, patients in both the TIC and TIC+ASP groups had reduced aggregation with 10 μmol/L ADP that was similar between groups, confirming that ticagrelor had fully suppressed the ADP‐mediated activation pathway in both groups. Conversely aggregation with 1 mmol/L AA was markedly reduced in the TIC+ASP group compared with the TIC group, indicating the presence of aspirin, which potently inhibits the aggregation response to AA by blocking synthesis of TxA<sub>2</sub>.<xref rid="jah35604-bib-0028" ref-type="ref"><sup>28</sup></xref>, <xref rid="jah35604-bib-0029" ref-type="ref"><sup>29</sup></xref> Having confirmed strong blockade of the ADP and TxA<sub>2</sub> activation pathways by TIC and ASP respectively, we observed that platelet aggregation responses to TRAP‐6 (protease activated (thrombin) receptor‐1 agonist) and U46619 (TxA<sub>2</sub> receptor agonist) were similar between the treatment groups. This finding replicates data from previous studies using platelets from healthy volunteers incubated <italic>ex vivo</italic> with prasugrel active metabolite or with ticagrelor<xref rid="jah35604-bib-0010" ref-type="ref"><sup>10</sup></xref>, <xref rid="jah35604-bib-0014" ref-type="ref"><sup>14</sup></xref>, <xref rid="jah35604-bib-0015" ref-type="ref"><sup>15</sup></xref> or from healthy volunteers receiving prasugrel,<xref rid="jah35604-bib-0030" ref-type="ref"><sup>30</sup></xref> and suggests that strong P2Y<sub>12</sub> blockers duplicate the inhibitory effect of aspirin on the thrombin and TxA<sub>2</sub> receptor activation pathways.</p>
              <p>By contrast, we found that the aggregation responses to CRP, which is a specific agonist of the platelet glycoprotein (GP) VI (collagen) receptor, were higher in the TIC group compared with the TIC+ASP group suggesting that TIC is insufficient to completely supress collagen‐mediated platelet activation. This effect was also observed in healthy volunteer studies,<xref rid="jah35604-bib-0014" ref-type="ref"><sup>14</sup></xref>, <xref rid="jah35604-bib-0015" ref-type="ref"><sup>15</sup></xref>, <xref rid="jah35604-bib-0030" ref-type="ref"><sup>30</sup></xref> although only at high concentrations of the collagen agonist, which has less specificity for the GPVI receptor than CRP.<xref rid="jah35604-bib-0031" ref-type="ref"><sup>31</sup></xref> The GPVI receptor is essential for normal haemostasis<xref rid="jah35604-bib-0032" ref-type="ref"><sup>32</sup></xref> and mediates platelet activation through downstream signalling pathways that are dependent on TxA<sub>2</sub> synthesis and thereby are highly sensitive to aspirin.<xref rid="jah35604-bib-0033" ref-type="ref"><sup>33</sup></xref> We were unable to demonstrate a difference between the treatment groups in surface expression of the activation markers PAC 1 and anti‐CD62P after stimulation with CRP, possibly reflecting limited sensitivity of this flow cytometry assay to differences in activation responses compared with the gold‐standard light transmission aggregation.<xref rid="jah35604-bib-0034" ref-type="ref"><sup>34</sup></xref>
</p>
              <p>Our findings also provide potential mechanistic explanations for differences in adverse events observed in recent randomized controlled trials of P2Y<sub>12</sub> antagonist monotherapy versus DAPT. In particular, they suggest that the lower incidence of bleeding in the P2Y<sub>12</sub> antagonist monotherapy groups in the TWILIGHT and SMART‐CHOICE trials<xref rid="jah35604-bib-0017" ref-type="ref"><sup>17</sup></xref>, <xref rid="jah35604-bib-0019" ref-type="ref"><sup>19</sup></xref> may be attributable to partial preservation of platelet GPVI‐mediated activation pathways in the monotherapy group, compared with more complete suppression from aspirin in the DAPT group. In the GLOBAL LEADERS study overall bleeding was similar in the P2Y<sub>12</sub> antagonist monotherapy and DAPT groups.<xref rid="jah35604-bib-0018" ref-type="ref"><sup>18</sup></xref> However, in a posthoc analysis of the acute coronary syndrome cohort, increased bleeding in the DAPT group compared with the P2Y<sub>12</sub> antagonist monotherapy group was observed between 1 and 12 months after treatment allocation <xref rid="jah35604-bib-0020" ref-type="ref"><sup>20</sup></xref>, supporting the notion that across all patient groups avoidance of aspirin diminishes bleeding. It is also noteworthy that despite different bleeding rates in the treatment groups, thrombotic outcomes were not more frequent in the P2Y<sub>12</sub> antagonist monotherapy groups.<xref rid="jah35604-bib-0017" ref-type="ref"><sup>17</sup></xref>, <xref rid="jah35604-bib-0018" ref-type="ref"><sup>18</sup></xref>, <xref rid="jah35604-bib-0019" ref-type="ref"><sup>19</sup></xref> Several potential explanations for this apparent mismatch have been proposed.<xref rid="jah35604-bib-0016" ref-type="ref"><sup>16</sup></xref>, <xref rid="jah35604-bib-0035" ref-type="ref"><sup>35</sup></xref> However, our data raise the additional possibility that the similar anti‐thrombotic effects of P2Y<sub>12</sub> antagonist monotherapy and DAPT could reflect their similar inhibitory effect on the platelet thrombin activation pathway, which is an essential component of the stepwise models of pathogenesis of atherothrombosis<xref rid="jah35604-bib-0023" ref-type="ref"><sup>23</sup></xref>, <xref rid="jah35604-bib-0024" ref-type="ref"><sup>24</sup></xref> but may be partially redundant with collagen‐mediated platelet activation in normal haemostasis.<xref rid="jah35604-bib-0032" ref-type="ref"><sup>32</sup></xref>, <xref rid="jah35604-bib-0036" ref-type="ref"><sup>36</sup></xref> Considered alongside the clinical outcome data, our findings support comprehensive platelet inhibition with DAPT early after PCI when thrombotic risk is highest. They suggest further the potential for subsequent cessation of aspirin to diminish bleeding by reducing platelet inhibition and by specifically minimising gastrointestinal tract bleeding for which aspirin is a contributory factor because of inhibition of gastroprotective prostanoids.<xref rid="jah35604-bib-0013" ref-type="ref"><sup>13</sup></xref>
</p>
              <sec id="jah35604-sec-0022">
                <title>Strengths and Limitations</title>
                <p>A major strength of the TEMPLATE study was that it enabled pharmacodynamic assessment of TIC compared to DAPT with TIC+ASP in a randomized setting. Allocation bias was avoided through concealed allocation. Blood samples were analyzed in a single laboratory, thereby avoiding inter‐laboratory variability. Laboratory personnel conducting the analyses were blinded to the group allocation. The broad selection of platelet activators confirmed that the platelet ADP and TxA<sub>2</sub> pathways were strongly inhibited by the study drugs (aggregation responses with ADP and AA), but also enabled evaluation of platelet pathways important in pathological thrombosis (aggregation responses TRAP‐6 and CRP).</p>
                <p>The main imitations were that the study is small, and the participants were recruited from a single center, thereby limiting the generalizability of the findings. The clinical teams were also not blinded to the treatment allocation of the participants. There is a small possibility that platelet responses to the treatment drugs could have been different in the study cases enrolled at 12 months after PCI compared with patients enrolled earlier after PCI, as were evaluated in the TWILIGHT and GLOBAL LEADERS studies.<xref rid="jah35604-bib-0016" ref-type="ref"><sup>16</sup></xref>, <xref rid="jah35604-bib-0018" ref-type="ref"><sup>18</sup></xref> The study necessarily evaluated platelet function ex vivo using tests that are insensitive to regulators of platelet activation released locally in the vasculature such as prostacyclin. Synthesis of this important negative regulator of platelet activation is inhibited by aspirin, thereby offsetting the main anti‐thrombotic effect of aspirin that occurs through inhibition of platelet TxA<sub>2</sub> synthesis.<xref rid="jah35604-bib-0037" ref-type="ref"><sup>37</sup></xref>, <xref rid="jah35604-bib-0038" ref-type="ref"><sup>38</sup></xref> This effect is unlikely to be detected in ex vivo platelet function tests thereby potentially leading to an overestimation of overall anti‐thrombotic effect of aspirin. The study was insufficiently powered to test whether the differences between the treatment groups were consistent across all patient subgroups such as diabetes mellitus versus no diabetes mellitus or smokers versus non‐smokers. Since these characteristics influence baseline platelet reactivity, this is an attractive area of future investigation.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah35604-sec-0023">
              <title>Conclusions</title>
              <p>Monotherapy with the strong P2Y<sub>12</sub> antagonist ticagrelor results in less complete inhibition of collagen GPVI‐mediated platelet activation when compared with DAPT with TIC+ASP. This finding may partially contribute to the increased bleeding in patients receiving DAPT compared with potent P2Y<sub>12</sub> antagonists.</p>
            </sec>
            <sec id="jah35604-sec-0025">
              <title>Sources of Funding</title>
              <p>The TEMPLATE study was funded through an Astra Zeneca Investigator sponsored study and supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The CTEU, part of the Bristol Trials Centre, receives National Institute for Health Research (NIHR) CTU support funding. The views expressed in this publication are those of the authors and not necessarily those of Astra Zeneca, the NHS, the National Institute for Health Research or the Department of Health and Social Care.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah35604-sec-0026">
              <title>Disclosures</title>
              <p>A.M. and T.J. have received speaker, consultancy fees from Astra‐Zeneca. The remaining authors have no disclosures to report.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah35604-sup-0001">
                <caption>
                  <p>
                    <bold>Tables S1–S4</bold>
                  </p>
                  <p>
                    <bold>Figures S1–S2</bold>
                  </p>
                </caption>
                <media xlink:href="JAH3-9-e016495-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah35604-sec-0024">
              <title>Acknowledgments</title>
              <p>This trial was delivered in collaboration with the Clinical Trials and Evaluation Unit (CTEU), Bristol Trials Centre, a UKCRC registered clinical trials unit. The authors thank Lucy Fitzgibbon for assistance in preparation of the manuscript.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah35604-bibl-0001">
              <title>References</title>
              <ref id="jah35604-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0001"><string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>SR</given-names></string-name>, <string-name><surname>Chrolavicius</surname><given-names>S</given-names></string-name>, <string-name><surname>Tognoni</surname><given-names>G</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KK</given-names></string-name>; <collab collab-type="authors">Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I</collab>
. <article-title>Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2001</year>;<volume>345</volume>:<fpage>494</fpage>–<lpage>502</lpage>.<pub-id pub-id-type="pmid">11519503</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0002"><string-name><surname>Mehta</surname><given-names>SR</given-names></string-name>, <string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>, <string-name><surname>Peters</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Bertrand</surname><given-names>ME</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>BS</given-names></string-name>, <string-name><surname>Natarajan</surname><given-names>MK</given-names></string-name>, <string-name><surname>Malmberg</surname><given-names>K</given-names></string-name>, <string-name><surname>Rupprecht</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name><surname>Chrolavicius</surname><given-names>S</given-names></string-name>, et al. <article-title>Clopidogrel in Unstable angina to prevent Recurrent Events trial I. Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: the PCI‐CURE study</article-title>. <source xml:lang="en">Lancet</source>. <year>2001</year>;<volume>358</volume>:<fpage>527</fpage>–<lpage>533</lpage>.<pub-id pub-id-type="pmid">11520521</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0003"><string-name><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Sousa‐Uva</surname><given-names>M</given-names></string-name>, <string-name><surname>Ahlsson</surname><given-names>A</given-names></string-name>, <string-name><surname>Alfonso</surname><given-names>F</given-names></string-name>, <string-name><surname>Banning</surname><given-names>AP</given-names></string-name>, <string-name><surname>Benedetto</surname><given-names>U</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>RA</given-names></string-name>, <string-name><surname>Collet</surname><given-names>JP</given-names></string-name>, <string-name><surname>Falk</surname><given-names>V</given-names></string-name>, <string-name><surname>Head</surname><given-names>SJ</given-names></string-name>, et al. <article-title>ESC/EACTS Guidelines on myocardial revascularization</article-title>. <source xml:lang="en">EuroIntervention</source>. <year>2018</year>;<volume>2019</volume>:<fpage>1435</fpage>–<lpage>1534</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35604-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0004"><string-name><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name><surname>Bueno</surname><given-names>H</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>RA</given-names></string-name>, <string-name><surname>Collet</surname><given-names>JP</given-names></string-name>, <string-name><surname>Costa</surname><given-names>F</given-names></string-name>, <string-name><surname>Jeppsson</surname><given-names>A</given-names></string-name>, <string-name><surname>Juni</surname><given-names>P</given-names></string-name>, <string-name><surname>Kastrati</surname><given-names>A</given-names></string-name>, <string-name><surname>Kolh</surname><given-names>P</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, et al. <article-title>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio‐Thoracic Surgery (EACTS)</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2018</year>;<volume>39</volume>:<fpage>213</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">28886622</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0005"><string-name><surname>Husted</surname><given-names>S</given-names></string-name>, <string-name><surname>Emanuelsson</surname><given-names>H</given-names></string-name>, <string-name><surname>Heptinstall</surname><given-names>S</given-names></string-name>, <string-name><surname>Sandset</surname><given-names>PM</given-names></string-name>, <string-name><surname>Wickens</surname><given-names>M</given-names></string-name>, <string-name><surname>Peters</surname><given-names>G</given-names></string-name>. <article-title>Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double‐blind comparison to clopidogrel with aspirin</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2006</year>;<volume>27</volume>:<fpage>1038</fpage>–<lpage>1047</lpage>.<pub-id pub-id-type="pmid">16476694</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0006"><string-name><surname>Mahaffey</surname><given-names>KW</given-names></string-name>, <string-name><surname>Wojdyla</surname><given-names>DM</given-names></string-name>, <string-name><surname>Carroll</surname><given-names>K</given-names></string-name>, <string-name><surname>Becker</surname><given-names>RC</given-names></string-name>, <string-name><surname>Storey</surname><given-names>RF</given-names></string-name>, <string-name><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Held</surname><given-names>C</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>CP</given-names></string-name>, <string-name><surname>James</surname><given-names>S</given-names></string-name>, <string-name><surname>Pieper</surname><given-names>KS</given-names></string-name>, et al. <article-title>Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial</article-title>. <source xml:lang="en">Circulation</source>. <year>2011</year>;<volume>124</volume>:<fpage>544</fpage>–<lpage>554</lpage>.<pub-id pub-id-type="pmid">21709065</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0007"><string-name><surname>Wallentin</surname><given-names>L</given-names></string-name>, <string-name><surname>Becker</surname><given-names>RC</given-names></string-name>, <string-name><surname>Budaj</surname><given-names>A</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>CP</given-names></string-name>, <string-name><surname>Emanuelsson</surname><given-names>H</given-names></string-name>, <string-name><surname>Held</surname><given-names>C</given-names></string-name>, <string-name><surname>Horrow</surname><given-names>J</given-names></string-name>, <string-name><surname>Husted</surname><given-names>S</given-names></string-name>, <string-name><surname>James</surname><given-names>S</given-names></string-name>, <string-name><surname>Katus</surname><given-names>H</given-names></string-name>, et al. <article-title>Ticagrelor versus clopidogrel in patients with acute coronary syndromes</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2009</year>;<volume>361</volume>:<fpage>1045</fpage>–<lpage>1057</lpage>.<pub-id pub-id-type="pmid">19717846</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0008"><string-name><surname>Becker</surname><given-names>RC</given-names></string-name>, <string-name><surname>Bassand</surname><given-names>JP</given-names></string-name>, <string-name><surname>Budaj</surname><given-names>A</given-names></string-name>, <string-name><surname>Wojdyla</surname><given-names>DM</given-names></string-name>, <string-name><surname>James</surname><given-names>SK</given-names></string-name>, <string-name><surname>Cornel</surname><given-names>JH</given-names></string-name>, <string-name><surname>French</surname><given-names>J</given-names></string-name>, <string-name><surname>Held</surname><given-names>C</given-names></string-name>, <string-name><surname>Horrow</surname><given-names>J</given-names></string-name>, <string-name><surname>Husted</surname><given-names>S</given-names></string-name>, et al. <article-title>Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>2933</fpage>–<lpage>2944</lpage>.<pub-id pub-id-type="pmid">22090660</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0009"><string-name><surname>Armstrong</surname><given-names>PCJ</given-names></string-name>, <string-name><surname>Dhanji</surname><given-names>ARA</given-names></string-name>, <string-name><surname>Tucker</surname><given-names>AT</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Warner</surname><given-names>TD</given-names></string-name>. <article-title>Reduction of platelet thromboxane A(2) production ex vivo and in vivo by clopidogrel therapy</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>:<fpage>613</fpage>–<lpage>615</lpage>.<pub-id pub-id-type="pmid">19995405</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0010"><string-name><surname>Kirkby</surname><given-names>NS</given-names></string-name>, <string-name><surname>Leadbeater</surname><given-names>PD</given-names></string-name>, <string-name><surname>Chan</surname><given-names>MV</given-names></string-name>, <string-name><surname>Nylander</surname><given-names>S</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Warner</surname><given-names>TD</given-names></string-name>. <article-title>Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2011</year>;<volume>9</volume>:<fpage>2103</fpage>–<lpage>2105</lpage>.<pub-id pub-id-type="pmid">21812912</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0011"><string-name><surname>Guidetti</surname><given-names>GF</given-names></string-name>, <string-name><surname>Lova</surname><given-names>P</given-names></string-name>, <string-name><surname>Bernardi</surname><given-names>B</given-names></string-name>, <string-name><surname>Campus</surname><given-names>F</given-names></string-name>, <string-name><surname>Baldanzi</surname><given-names>G</given-names></string-name>, <string-name><surname>Graziani</surname><given-names>A</given-names></string-name>, <string-name><surname>Balduini</surname><given-names>C</given-names></string-name>, <string-name><surname>Torti</surname><given-names>M</given-names></string-name>. <article-title>The Gi‐coupled P2Y12 receptor regulates diacylglycerol‐mediated signaling in human platelets</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2008</year>;<volume>283</volume>:<fpage>28795</fpage>–<lpage>28805</lpage>.<pub-id pub-id-type="pmid">18755689</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0012"><string-name><surname>Gargiulo</surname><given-names>G</given-names></string-name>, <string-name><surname>Windecker</surname><given-names>S</given-names></string-name>, <string-name><surname>Vranckx</surname><given-names>P</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Valgimigli</surname><given-names>M</given-names></string-name>. <article-title>A critical appraisal of aspirin in secondary prevention: is less more?</article-title><source xml:lang="en">Circulation</source>. <year>2016</year>;<volume>134</volume>:<fpage>1881</fpage>–<lpage>1906</lpage>.<pub-id pub-id-type="pmid">27920074</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0013"><string-name><surname>Warner</surname><given-names>TD</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>PCJ</given-names></string-name>, <string-name><surname>Curzen</surname><given-names>NP</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>JA</given-names></string-name>. <article-title>Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y(12) receptor antagonists?</article-title><source xml:lang="en">Heart</source>. <year>2010</year>;<volume>96</volume>:<fpage>1693</fpage>–<lpage>1694</lpage>.<pub-id pub-id-type="pmid">20956485</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0014"><string-name><surname>Armstrong</surname><given-names>PC</given-names></string-name>, <string-name><surname>Leadbeater</surname><given-names>PD</given-names></string-name>, <string-name><surname>Chan</surname><given-names>MV</given-names></string-name>, <string-name><surname>Kirkby</surname><given-names>NS</given-names></string-name>, <string-name><surname>Jakubowski</surname><given-names>JA</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Warner</surname><given-names>TD</given-names></string-name>. <article-title>In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2011</year>;<volume>9</volume>:<fpage>552</fpage>–<lpage>561</lpage>.<pub-id pub-id-type="pmid">21143373</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0015"><string-name><surname>Scavone</surname><given-names>M</given-names></string-name>, <string-name><surname>Femia</surname><given-names>EA</given-names></string-name>, <string-name><surname>Caroppo</surname><given-names>V</given-names></string-name>, <string-name><surname>Cattaneo</surname><given-names>M</given-names></string-name>. <article-title>Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>3347</fpage>–<lpage>3356</lpage>.<pub-id pub-id-type="pmid">26516174</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0016"><string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Cao</surname><given-names>D</given-names></string-name>, <string-name><surname>Baber</surname><given-names>U</given-names></string-name>. <article-title>Ticagrelor monotherapy after coronary stenting: is the glass half full or half empty?</article-title><source xml:lang="en">J Am Coll Cardiol</source>. <year>2019</year>;<volume>74</volume>:<fpage>2235</fpage>–<lpage>2237</lpage>.<pub-id pub-id-type="pmid">31672178</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0017"><string-name><surname>Hahn</surname><given-names>JY</given-names></string-name>, <string-name><surname>Song</surname><given-names>YB</given-names></string-name>, <string-name><surname>Oh</surname><given-names>JH</given-names></string-name>, <string-name><surname>Chun</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Park</surname><given-names>YH</given-names></string-name>, <string-name><surname>Jang</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Im</surname><given-names>ES</given-names></string-name>, <string-name><surname>Jeong</surname><given-names>JO</given-names></string-name>, <string-name><surname>Cho</surname><given-names>BR</given-names></string-name>, <string-name><surname>Oh</surname><given-names>SK</given-names></string-name>, et al. <article-title>Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART‐CHOICE randomized clinical trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2019</year>;<volume>321</volume>:<fpage>2428</fpage>–<lpage>2437</lpage>.<pub-id pub-id-type="pmid">31237645</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0018"><string-name><surname>Vranckx</surname><given-names>P</given-names></string-name>, <string-name><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name><surname>Juni</surname><given-names>P</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>C</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Heg</surname><given-names>D</given-names></string-name>, <string-name><surname>van Es</surname><given-names>GA</given-names></string-name>, <string-name><surname>McFadden</surname><given-names>EP</given-names></string-name>, <string-name><surname>Onuma</surname><given-names>Y</given-names></string-name>, <string-name><surname>van Meijeren</surname><given-names>C</given-names></string-name>, et al. <article-title>Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug‐eluting stent: a multicentre, open‐label, randomised superiority trial</article-title>. <source xml:lang="en">Lancet</source>. <year>2018</year>;<volume>392</volume>:<fpage>940</fpage>–<lpage>949</lpage>.<pub-id pub-id-type="pmid">30166073</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0019"><string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Baber</surname><given-names>U</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>SK</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Briguori</surname><given-names>C</given-names></string-name>, <string-name><surname>Cha</surname><given-names>JY</given-names></string-name>, <string-name><surname>Collier</surname><given-names>T</given-names></string-name>, <string-name><surname>Dangas</surname><given-names>G</given-names></string-name>, <string-name><surname>Dudek</surname><given-names>D</given-names></string-name>, et al. <article-title>Ticagrelor with or without aspirin in high‐risk patients after PCI</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<volume>381</volume>:<fpage>2032</fpage>–<lpage>2042</lpage>.<pub-id pub-id-type="pmid">31556978</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0020"><string-name><surname>Tomaniak</surname><given-names>M</given-names></string-name>, <string-name><surname>Chichareon</surname><given-names>P</given-names></string-name>, <string-name><surname>Onuma</surname><given-names>Y</given-names></string-name>, <string-name><surname>Deliargyris</surname><given-names>EN</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>K</given-names></string-name>, <string-name><surname>Kogame</surname><given-names>N</given-names></string-name>, <string-name><surname>Modolo</surname><given-names>R</given-names></string-name>, <string-name><surname>Chang</surname><given-names>CC</given-names></string-name>, <string-name><surname>Rademaker‐Havinga</surname><given-names>T</given-names></string-name>, <string-name><surname>Storey</surname><given-names>RF</given-names></string-name>, et al. <article-title>Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2019</year>;<volume>4</volume>:<fpage>1092</fpage>–<lpage>1101</lpage>.<pub-id pub-id-type="pmid">31557763</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0021"><string-name><surname>Baos</surname><given-names>S</given-names></string-name>, <string-name><surname>Underwood</surname><given-names>W</given-names></string-name>, <string-name><surname>Culliford</surname><given-names>L</given-names></string-name>, <string-name><surname>Reeves</surname><given-names>BC</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>CA</given-names></string-name>, <string-name><surname>Bowles</surname><given-names>R</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>T</given-names></string-name>, <string-name><surname>Baumbach</surname><given-names>A</given-names></string-name>, <string-name><surname>Mumford</surname><given-names>A</given-names></string-name>. <article-title>Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial</article-title>. <source xml:lang="en">Trials</source>. <year>2017</year>;<volume>18</volume>:<fpage>529</fpage>.<pub-id pub-id-type="pmid">29121979</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0022"><string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Rao</surname><given-names>SV</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name><surname>Caixeta</surname><given-names>A</given-names></string-name>, <string-name><surname>Eikelboom</surname><given-names>J</given-names></string-name>, <string-name><surname>Kaul</surname><given-names>S</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Menon</surname><given-names>V</given-names></string-name>, <string-name><surname>Nikolsky</surname><given-names>E</given-names></string-name>, et al. <article-title>Standardized bleeding definitions for cardiovascular clinical trials a consensus report from the bleeding academic research consortium</article-title>. <source xml:lang="en">Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>2736</fpage>–<lpage>2747</lpage>.<pub-id pub-id-type="pmid">21670242</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0023"><string-name><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Capodanno</surname><given-names>D</given-names></string-name>, <string-name><surname>Goto</surname><given-names>S</given-names></string-name>. <article-title>Platelet thrombin receptor antagonism and atherothrombosis</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2010</year>;<volume>31</volume>:<fpage>17</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">19948715</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0024"><string-name><surname>Reininger</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Bernlochner</surname><given-names>I</given-names></string-name>, <string-name><surname>Penz</surname><given-names>SM</given-names></string-name>, <string-name><surname>Ravanat</surname><given-names>C</given-names></string-name>, <string-name><surname>Smethurst</surname><given-names>P</given-names></string-name>, <string-name><surname>Farndale</surname><given-names>RW</given-names></string-name>, <string-name><surname>Gachet</surname><given-names>C</given-names></string-name>, <string-name><surname>Brandl</surname><given-names>R</given-names></string-name>, <string-name><surname>Siess</surname><given-names>W</given-names></string-name>. <article-title>A 2‐step mechanism of arterial thrombus formation induced by human atherosclerotic plaques</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>1147</fpage>–<lpage>1158</lpage>.<pub-id pub-id-type="pmid">20223370</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0025"><string-name><surname>Kuijpers</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Gilio</surname><given-names>K</given-names></string-name>, <string-name><surname>Reitsma</surname><given-names>S</given-names></string-name>, <string-name><surname>Nergiz‐Unal</surname><given-names>R</given-names></string-name>, <string-name><surname>Prinzen</surname><given-names>L</given-names></string-name>, <string-name><surname>Heeneman</surname><given-names>S</given-names></string-name>, <string-name><surname>Lutgens</surname><given-names>E</given-names></string-name>, <string-name><surname>van Zandvoort</surname><given-names>MA</given-names></string-name>, <string-name><surname>Nieswandt</surname><given-names>B</given-names></string-name>, <string-name><surname>Egbrink</surname><given-names>MG</given-names></string-name>, et al. <article-title>Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2009</year>;<volume>7</volume>:<fpage>152</fpage>–<lpage>161</lpage>.<pub-id pub-id-type="pmid">18983512</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0026"><string-name><surname>Joshi</surname><given-names>RR</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>R</given-names></string-name>, <string-name><surname>Morton</surname><given-names>AC</given-names></string-name>, <string-name><surname>Ecob</surname><given-names>R</given-names></string-name>, <string-name><surname>Judge</surname><given-names>HM</given-names></string-name>, <string-name><surname>Wales</surname><given-names>C</given-names></string-name>, <string-name><surname>Walker</surname><given-names>JV</given-names></string-name>, <string-name><surname>Karunakaran</surname><given-names>A</given-names></string-name>, <string-name><surname>Storey</surname><given-names>RF</given-names></string-name>. <article-title>Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes</article-title>. <source xml:lang="en">Platelets</source>. <year>2014</year>;<volume>25</volume>:<fpage>416</fpage>–<lpage>422</lpage>.<pub-id pub-id-type="pmid">24111601</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0027"><string-name><surname>Thomas</surname><given-names>MR</given-names></string-name>, <string-name><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Bonaca</surname><given-names>MP</given-names></string-name>, <string-name><surname>Ajjan</surname><given-names>RA</given-names></string-name>, <string-name><surname>Judge</surname><given-names>HM</given-names></string-name>, <string-name><surname>Rollini</surname><given-names>F</given-names></string-name>, <string-name><surname>Franchi</surname><given-names>F</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Kuder</surname><given-names>JF</given-names></string-name>, et al. <article-title>Consistent platelet inhibition with ticagrelor 60 mg twice‐daily following myocardial infarction regardless of diabetes status</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>2017</year>;<volume>117</volume>:<fpage>940</fpage>–<lpage>947</lpage>.<pub-id pub-id-type="pmid">28300867</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0028"><string-name><surname>Tantry</surname><given-names>US</given-names></string-name>, <string-name><surname>Bonello</surname><given-names>L</given-names></string-name>, <string-name><surname>Aradi</surname><given-names>D</given-names></string-name>, <string-name><surname>Price</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Jeong</surname><given-names>YH</given-names></string-name>, <string-name><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Stone</surname><given-names>GW</given-names></string-name>, <string-name><surname>Curzen</surname><given-names>N</given-names></string-name>, <string-name><surname>Geisler</surname><given-names>T</given-names></string-name>, <string-name><surname>Ten Berg</surname><given-names>J</given-names></string-name>, et al. <article-title>Consensus and update on the definition of on‐treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>:<fpage>2261</fpage>–<lpage>2273</lpage>.<pub-id pub-id-type="pmid">24076493</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0029"><string-name><surname>Snoep</surname><given-names>JD</given-names></string-name>, <string-name><surname>Hovens</surname><given-names>MM</given-names></string-name>, <string-name><surname>Eikenboom</surname><given-names>JC</given-names></string-name>, <string-name><surname>van der Bom</surname><given-names>JG</given-names></string-name>, <string-name><surname>Huisman</surname><given-names>MV</given-names></string-name>. <article-title>Association of laboratory‐defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Arch Intern Med</source>. <year>2007</year>;<volume>167</volume>:<fpage>1593</fpage>–<lpage>1599</lpage>.<pub-id pub-id-type="pmid">17698681</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0030"><string-name><surname>Leadbeater</surname><given-names>PDM</given-names></string-name>, <string-name><surname>Kirkby</surname><given-names>NS</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>S</given-names></string-name>, <string-name><surname>Dhanji</surname><given-names>AR</given-names></string-name>, <string-name><surname>Tucker</surname><given-names>AT</given-names></string-name>, <string-name><surname>Milne</surname><given-names>GL</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Warner</surname><given-names>TD</given-names></string-name>. <article-title>Aspirin has little additional anti‐platelet effect in healthy volunteers receiving prasugrel</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2011</year>;<volume>9</volume>:<fpage>2050</fpage>–<lpage>2056</lpage>.<pub-id pub-id-type="pmid">21794076</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0031"><string-name><surname>Miura</surname><given-names>Y</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>T</given-names></string-name>, <string-name><surname>Jung</surname><given-names>SM</given-names></string-name>, <string-name><surname>Moroi</surname><given-names>M</given-names></string-name>. <article-title>Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2002</year>;<volume>277</volume>:<fpage>46197</fpage>–<lpage>46204</lpage>.<pub-id pub-id-type="pmid">12356768</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0032"><string-name><surname>Nurden</surname><given-names>AT</given-names></string-name>. <article-title>Clinical significance of altered collagen‐receptor functioning in platelets with emphasis on glycoprotein VI</article-title>. <source xml:lang="en">Blood Rev</source>. <year>2019</year>;<volume>38</volume>:<fpage>100592</fpage>.<pub-id pub-id-type="pmid">31351674</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0033"><string-name><surname>Clark</surname><given-names>JC</given-names></string-name>, <string-name><surname>Kavanagh</surname><given-names>DM</given-names></string-name>, <string-name><surname>Watson</surname><given-names>S</given-names></string-name>, <string-name><surname>Pike</surname><given-names>JA</given-names></string-name>, <string-name><surname>Andrews</surname><given-names>RK</given-names></string-name>, <string-name><surname>Gardiner</surname><given-names>EE</given-names></string-name>, <string-name><surname>Poulter</surname><given-names>NS</given-names></string-name>, <string-name><surname>Hill</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Watson</surname><given-names>SP</given-names></string-name>. <article-title>Adenosine and forskolin inhibit platelet aggregation by collagen but not the proximal signalling events</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>2019</year>;<volume>119</volume>:<fpage>1124</fpage>–<lpage>1137</lpage>.<pub-id pub-id-type="pmid">31129912</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0034"><string-name><surname>Frelinger</surname><given-names>AL</given-names><suffix>III</suffix></string-name>, <string-name><surname>Gachet</surname><given-names>C</given-names></string-name>, <string-name><surname>Mumford</surname><given-names>AD</given-names></string-name>, <string-name><surname>Noris</surname><given-names>P</given-names></string-name>, <string-name><surname>Mezzano</surname><given-names>D</given-names></string-name>, <string-name><surname>Harrison</surname><given-names>P</given-names></string-name>, <string-name><surname>Gresele</surname><given-names>P</given-names></string-name>; <collab collab-type="authors">Subcommittee on Platelet P</collab>
. <article-title>Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2018</year>;<volume>16</volume>:<fpage>2341</fpage>–<lpage>2346</lpage>.<pub-id pub-id-type="pmid">30284374</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0035"><string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>. <article-title>Aspirin‐still the GLOBAL LEADER in antiplatelet therapy</article-title>. <source xml:lang="en">Lancet</source>. <year>2018</year>;<volume>392</volume>:<fpage>896</fpage>–<lpage>897</lpage>.<pub-id pub-id-type="pmid">30166072</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0036"><string-name><surname>Zahid</surname><given-names>M</given-names></string-name>, <string-name><surname>Mangin</surname><given-names>P</given-names></string-name>, <string-name><surname>Loyau</surname><given-names>S</given-names></string-name>, <string-name><surname>Hechler</surname><given-names>B</given-names></string-name>, <string-name><surname>Billiald</surname><given-names>P</given-names></string-name>, <string-name><surname>Gachet</surname><given-names>C</given-names></string-name>, <string-name><surname>Jandrot‐Perrus</surname><given-names>M</given-names></string-name>. <article-title>The future of glycoprotein VI as an antithrombotic target</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2012</year>;<volume>10</volume>:<fpage>2418</fpage>–<lpage>2427</lpage>.<pub-id pub-id-type="pmid">23020554</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0037"><string-name><surname>FitzGerald</surname><given-names>GA</given-names></string-name>, <string-name><surname>Oates</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hawiger</surname><given-names>J</given-names></string-name>, <string-name><surname>Maas</surname><given-names>RL</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>LJ</given-names><suffix>II</suffix></string-name>, <string-name><surname>Lawson</surname><given-names>JA</given-names></string-name>, <string-name><surname>Brash</surname><given-names>AR</given-names></string-name>. <article-title>Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man</article-title>. <source xml:lang="en">J Clin Invest</source>. <year>1983</year>;<volume>71</volume>:<fpage>676</fpage>–<lpage>688</lpage>.<pub-id pub-id-type="pmid">6338043</pub-id></mixed-citation>
              </ref>
              <ref id="jah35604-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah35604-cit-0038"><string-name><surname>Warner</surname><given-names>TD</given-names></string-name>, <string-name><surname>Nylander</surname><given-names>S</given-names></string-name>, <string-name><surname>Whatling</surname><given-names>C</given-names></string-name>. <article-title>Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapy</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>. <year>2011</year>;<volume>72</volume>:<fpage>619</fpage>–<lpage>633</lpage>.<pub-id pub-id-type="pmid">21320154</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
